Core Viewpoint - The company operates in the medical device distribution industry, focusing on high-value medical consumables and IVD diagnostic products, with a strategy to enhance its market share through differentiated operational capabilities and digital applications [2] Group 1: Industry Overview - The medical device distribution industry is characterized by a relatively fragmented market share for the company's core products, which include vascular intervention and surgical products, as well as IVD diagnostic products [2] - The company aims to leverage national sales networks, specialized operational capabilities, and digital development applications to differentiate itself from traditional medical device distributors and pharmaceutical wholesalers [2] Group 2: Business Strategy - The company plans to capitalize on existing mature market shares in the medical device distribution sector, particularly in the context of centralized procurement policies [2] - The company will actively pursue the commercialization of innovative medical devices, supported by encouraging policies for innovation [2] - Focus on centralized management supply for key hospitals during the full implementation phase of the medical reform DRG policy represents a new market segment for the company [2] Group 3: Competitive Positioning - The company's operational capabilities and digital applications are expected to enhance its position in both existing and emerging markets within the medical device distribution field [2] - The company aims for steady growth to improve its industry standing by learning from competitors and maintaining a robust competitive edge [2]

Group 1 - The company emphasizes the importance of communication and interaction with investors, maintaining a positive relationship through various channels [1] - The company commits to disclosing information that meets legal and regulatory standards in the future [1]

（文章来源：证券日报） 证券日报网讯 12月26日，建发致新发布公告称，公司及控股子公司未对合并报表外单位提供担保。公 司无逾期担保的情形，不存在涉及诉讼的担保及因担保被判决败诉而应承担损失等情形。 ...

Core Viewpoint - The company held its third board meeting on December 26, 2025, where several important resolutions were passed, including adjustments to fundraising projects, the addition of implementation entities, and the establishment of a high-level compensation system [1] Group 1: Fundraising Project Adjustments - The board approved a proposal to extend the construction period for the "Information System Upgrade Project" and the "Medical Consumables Centralized Operation Service Project," optimizing the internal investment structure to enhance fundraising efficiency [2] - The addition of an implementation entity for the "Medical Consumables Centralized Operation Service Project" was also approved, pending shareholder meeting review [2][6] Group 2: Fundraising Replacement and Compliance - The board approved a proposal to use raised funds to replace previously invested self-raised funds for fundraising projects and issuance costs, which complies with regulatory requirements and does not affect the normal implementation of fundraising projects [4] - The accounting firm provided a verification report, and the sponsor also issued a no-objection opinion regarding this replacement [4][3] Group 3: Governance Structure and Management Optimization - The board approved the establishment of a "Director and Senior Management Compensation Management System," which will be submitted for shareholder meeting review [5] - A proposal to adjust the company's organizational structure for 2026 was also approved to further optimize the management system [5] Group 4: Upcoming Shareholder Meeting - The board decided to hold the first temporary shareholder meeting of 2026 on January 13, 2026, to submit the aforementioned proposals for shareholder voting [6] - The series of resolutions passed by the board reflects the company's emphasis on the standardized use of raised funds and strategic development, which will help optimize resource allocation and enhance core competitiveness [6]

证券日报网讯12月26日，建发致新（301584）发布公告称，公司将于2026年1月13日14：30召开2026年 第一次临时股东会。 ...

Group 1 - The core point of the article is that Jianfa Zhixin (301584) reported its shareholder count as of December 19, with a total of 28,857 shareholders [1]

证券日报网讯12月26日，建发致新（301584）在互动平台回答投资者提问时表示，公司目前的主要营业 利润来源于医疗器械产品分销业务、直销业务和服务业务(SPD管理服务为主)。公司的业务通过自主研 发和运营的"业务平台系统"等进行全流程管理，但公司本身不通过出售软件或者软件服务作为主要收入 来源。 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-022 上海建发致新医疗科技集团股份有限公司 关于为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 上海建发致新医疗科技集团股份有限公司（以下简称"公司"或"建发致 新"）及控股子公司提供担保总额超过公司最近一期经审计净资产100%，对资产 负债率超过70%的控股子公司预计担保金额超过公司最近一期经审计净资产50%， 前述担保均为对公司合并报表范围内子公司的担保，财务风险处于公司可控范围内， 提请投资者充分关注担保风险。 一、对外担保情况概述 根据公司经营发展战略、资金预算和资金安全等需要，自公司2024年年度股 东大会之日起，至2025年年度股东会召开之日止，公司及控股子公司拟向各银行等 金融机构申请综合授信总额不超过人民币150亿元，以上事项已经公司2024年年度股 东大会和2025年第二次临时股东大会审议通过。 鉴于上述授信总额中部分授信额度的融资主体为公司控股子公司，为保障子公 司顺利申请授信额度，自公司2024年年度股东大会之日起，至2025 ...

证券代码：301584 证券简称：建发致新 公告编号：2025-020 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）于2025年12 月26日召开第三届董事会第十二次会议，审议通过《关于使用募集资金置换预先 已投入募投项目及已支付发行费用的自筹资金的议案》，同意公司使用募集资金 置换预先已投入募投项目及已支付发行费用的自筹资金，置换金额为人民币 12,825.19万元，公司保荐机构中信证券股份有限公司（以下简称"中信证券"） 对该事项发表了核查意见。现将具体情况公告如下： 及已支付发行费用的自筹资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海建发致新医疗科技集团股份有限公司 关于使用募集资金置换预先已投入募投项目 一、 募集资金基本情况 根据中国证券监督管理委员会《关于同意上海建发致新医疗科技集团股份有 限公司首次公开发行股票注册的批复》（证监许可[2025]1337号）并经深圳证券 交易所同意，公司首次公开发行人民币普通股（A股）股票63,193,277股，发行 价格为人民币7.05元/股，募集资金总额44,551.26万元，扣除 ...

中信证券股份有限公司 关于上海建发致新医疗科技集团股份有限公司 部分募投项目新增实施主体的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为上海 建发致新医疗科技集团股份有限公司（以下简称"建发致新"或"公司"）首次 公开发行股票和持续督导工作的保荐机构，根据《中华人民共和国公司法》《中 华人民共和国证券法》《证券发行上市保荐业务管理办法》《深圳证券交易所创业 板股票上市规则》等相关规定，对公司部分募投项目新增实施主体的事项进行了 核查，具体情况如下： 一、募集资金的基本情况 根据中国证券监督管理委员会出具的《关于同意上海建发致新医疗科技集团 股份有限公司首次公开发行股票注册的批复》（证监许可〔2025〕1337 号），公 司获准首次向社会公众公开发行人民币普通股（A 股）股票（以下简称"本次发 行"）63,193,277 股，发行价格为人民币 7.05 元/股，募集资金总额为人民币 44,551.26 万元，扣除各项发行费用后募集资金净额为人民币 36,333.45 万元。上 述募集资金已于 2025 年 9 月 22 日划至公司指定账户，容诚会计师事务所（特殊 普通合伙）对募集资金到 ...